Skip to main content

Security report for ultsolrems.com

Alexion Pharmaceuticals, Inc. · Healthcare · United States

Low risk. 5 critical or high findings in Email security, GDPR outside view and 1 other check.

Security score

77/100

Risk levelLow

0–100, higher is better. How it is calculated

The website ultsolrems.com serves as the official portal for the ULTOMIRIS and SOLIRIS Risk Evaluation and Mitigation Strategy (REMS) program managed by Alexion Pharmaceuticals, Inc. It provides critical information and resources aimed at healthcare providers, pharmacies, and healthcare settings to ensure safe prescribing and dispensing of these medications. The site emphasizes patient safety through vaccination and awareness of meningococcal infection risks, aligning with FDA REMS requirements. The business model is focused on regulatory compliance and education within the pharmaceutical healthcare sector, targeting US-based healthcare professionals and institutions.

Scanned

NIS2 and GDPR posture

GDPR outside view
65/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

    • High

      No SPF record found

      SPF helps prevent email spoofing

      What to do: Add SPF record: "v=spf1 include:_spf.yourmailprovider.com ~all"

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching ultsolrems.com

This scan found 15 issues across 5 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
82
Security headers
100
Email security
40
DNS health
75
Network security
100
GDPR outside view
65
Average
77

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Alexion Pharmaceuticals leverages this dedicated REMS website to maintain regulatory compliance and support its specialized pharmaceutical products. The site’s integration with parent company domains and provision of official prescribing information and medication guides reinforce its authoritative position. The business operates in a niche healthcare segment with a clear focus on risk mitigation and patient safety. The presence of certification forms and safety brochures indicates a structured approach to stakeholder engagement. The domain age and WHOIS data align with the recent launch of the combined REMS program, reflecting a strategic digital initiative to consolidate REMS efforts for ULTOMIRIS and SOLIRIS.

Security posture

The website demonstrates a solid security posture with HTTPS enabled and use of Google reCAPTCHA to mitigate automated abuse. However, the absence of DNSSEC, security headers, and explicit security or incident response policies suggests room for improvement. No vulnerabilities or exposed sensitive data were detected in the HTML content. The lack of a cookie consent mechanism may impact privacy compliance, especially under GDPR. Overall, the security maturity is moderate, suitable for a healthcare regulatory site but requiring enhancements to meet best practices fully.

Recommendations

  1. Enable DNSSEC on the domain to enhance DNS security and prevent spoofing.
  2. Implement standard security headers such as Content Security Policy (CSP), HSTS, X-Frame-Options, and X-Content-Type-Options.
  3. Publish a clear security policy and incident response contact information to improve transparency and trust.
  4. Add a cookie consent banner or mechanism to comply with privacy regulations and improve user trust.
  5. Regularly audit third-party libraries and scripts to ensure no vulnerabilities are introduced.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Alexion Pharmaceuticals, Inc.
Description
The website provides information about the ULTOMIRIS and SOLIRIS Risk Evaluation and Mitigation Strategy (REMS) program to mitigate serious meningococcal infection risks for patients receiving complement inhibitors.
Key services
REMS certification for prescribers, REMS certification for healthcare settings and pharmacies, Provision of educational and safety resources, Adverse event reporting
Content quality
good
Branding
consistent

Technology

Stack
JavaScript, jQuery, Bootstrap, Quill Editor, Auth0 SPA JS, MSAL Browser, Google reCAPTCHA, Google Maps API
Frameworks
Bootstrap
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
80/100
Good practices seen
  • HTTPS enabled
  • Use of Google reCAPTCHA for bot protection
  • No exposed sensitive data in HTML

Analytics and tracking

Tracking level
minimal
Privacy practices
basic

Advertising

Marketing tools
Google reCAPTCHA, Auth0 SPA JS, MSAL Browser
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a specialized REMS program portal for ULTOMIRIS and SOLIRIS medications.
  2. Content is professional, medically focused, and targeted at healthcare providers and pharmacies.
  3. No signs of malicious or suspicious content.
  4. No cookie consent mechanism detected, which may affect privacy compliance.
  5. No explicit security policy or incident response information publicly available.
  6. WHOIS data shows a recently registered domain consistent with the program launch.
  7. Website uses modern JavaScript libraries and APIs for functionality.
  8. No social media links or email addresses explicitly provided on the main page.
Technical notes

Notes

The website uses a modern technology stack including Bootstrap for responsive design, Quill for rich text editing, and authentication libraries such as Auth0 SPA JS and MSAL Browser. Hosting appears to be on AWS infrastructure, inferred from DNS servers. Performance is moderate with asynchronous loading of scripts and use of CDN-hosted resources. SEO is supported by proper meta tags and structured navigation. Accessibility is basic but could be improved. No CMS was explicitly detected, suggesting a custom or proprietary platform. Overall, the technical implementation is solid but could benefit from enhanced accessibility and security features.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with ultsolrems.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review ultsolrems.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.